Hormone Resistant Prostate Cancer Completed Phase 1 / 2 Trials for Cixutumumab (DB12250)

Also known as: Hormone-Resistant Prostate Cancer

IndicationStatusPhase
DBCOND0038482 (Hormone Resistant Prostate Cancer)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01026623Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate CancerTreatment